Short Interest in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Drops By 64.8%

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 9,000 shares, a decrease of 64.8% from the June 30th total of 25,600 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 35,100 shares, the days-to-cover ratio is presently 0.3 days.

Sol-Gel Technologies Trading Up 11.4 %

Shares of SLGL traded up $0.05 during mid-day trading on Friday, hitting $0.50. 1,448,285 shares of the company’s stock were exchanged, compared to its average volume of 146,584. The firm has a market capitalization of $13.96 million, a P/E ratio of -0.60 and a beta of 1.54. Sol-Gel Technologies has a fifty-two week low of $0.42 and a fifty-two week high of $3.92. The business’s 50 day moving average is $0.82 and its two-hundred day moving average is $0.96.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings data on Monday, May 20th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). The firm had revenue of $0.47 million during the quarter, compared to analyst estimates of $1.30 million. Sol-Gel Technologies had a negative net margin of 1,329.13% and a negative return on equity of 56.20%. On average, equities research analysts forecast that Sol-Gel Technologies will post -0.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright dropped their price objective on Sol-Gel Technologies from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, May 20th.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.